Search
  • About Us
    • Company profile
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline overview
    • CDNF
    • Next generation xCDNF
    • Lymfactin
    • Scientific publications
  • Investors
    • Investors
    • Releases
    • Analyst Coverage
    • Financial Calendar
    • General Meetings
    • Financial Information
    • Share Information
    • Share Monitor
    • Investor Relations
    • Corporate Governance
  • News & Events
    • Herantis in the News
    • Events
    • Releases
    • Public materials
    • Video Presentations
    • Newsletter
  • Patients
    • Overview & Contact Us
    • Parkinson’s Disease
    • Lymphedema
    • Community Resources
  • Contact
  • FIN
Search

Latest releases

  • CDNF releases
  • Earnings Release
  • First north
  • General releases
  • Insider trading
  • Lymfactin releases
  • Newsletter
  • Press Release
  • Clear
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 20.12.2016
    FN
    Herantis Pharma Plc’s financial reporting schedule and annual general meeting in 2017
  • 13.12.2016
    FN
    Herantis Pharma Oyj – Manager’s Transactions
  • 12.12.2016
    CR, FN
    Herantis Pharma’s Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program
  • 25.10.2016
    CR, FN
    Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson’s study
  • 25.08.2016
    FN
    Herantis Pharma Plc’s Half year financial report January 1-June 30, 2016 (unaudited)
  • 08.08.2016
    FN
    EU funding application coordinated by Herantis Pharma has passed evaluation phase
  • 19.05.2016
    FN
    Herantis Pharma Plc’s Board decision on new stock option program for senior employees
  • 18.05.2016
    FN, LR
    Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema
  • 11.04.2016
    FN
    Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders
  • 29.03.2016
    FN
    Herantis Pharma receives orphan designation of CDNF for treatment of ALS
  • « Previous page
  • Page 1
  • Page 2
  • Next page »

Quick links

Herantis in the News »
Events »
Releases »
Public materials »
Video Presentations »
Newsletter »

HERANTIS PHARMA Plc
Bertel Jungin Aukio 1
FIN-02600 Espoo

Tel: +358 9 222 1195
Email: info (at) herantis.com
VAT number FI21986657

  • Legal notice
  • Privacy notice
  • Sign up for our bi-monthly newsletter

Copyright © HERANTIS PHARMA Plc. All rights reserved.

Cookies
This website uses cookies and Google Analytics. We use cookies and Google Analytics to adapt the website according to your preferences and to collect information about the use of the website. For more information regarding cookies we request you to review our privacy notice. The following terms and conditions are applied to the use of this website. By continuing to use this website you accept such terms and conditions.
OK
Privacy notice
Legal notice
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.